Table 1:

Recommendations for sleep and circadian research aimed at the prevention or treatment of Alzheimer Disease (AD)

	No AD pathology	Preclinical (asymptomatic) AD	Symptomatic AD
Basic research	Identify mechanisms linking sleep to Aβ/tau production/clearance	Examine effect of different sleep/circadian-promoting drugs or interventions on tau aggregation, inflammation, synaptic function, other degenerative processes in preclinical models.
Clinical research	Longitudinal (20 + years) followup studies	AD biomarker assessment regardless of cognitive status	Test effect of existing treatments on cognitive outcomes, with specific attention to safety & tolerability
	Objective measures of sleep and circadian function	Objective measures of sleep and circadian function
	Analytic methods for non-linear risk factors (e.g. sleep time)	Assess for obstructive sleep apnea and other sleep disorders	Identify and test new non-sedating therapies for sleep-circadian disruption in dementia patients
	Assess for obstructive sleep apnea and other sleep disorders	Test effect of existing treatments (ex: PAP for OSA; medication for insomnia) on AD markers
	Genetic, race/ethnicity	Genetic, race/ethnicity
	Sleep-circadian biomarkers
Trials and implementation	Screening measures for abnormal sleep/circadian function
	Tractable markers of abnormal sleep/circadian dysfunction
	Determination of a goal range.
	Education and outreach